Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00199134
Status:
COMPLETED
Last Update Posted:
2015-01-06
First Post:
2005-09-12
Brief Title:
FRAGRANCE Part A Safety Study to Find a Genetic Signature of de Novo Resistance to Letrozole
Sponsor:
Jules Bordet Institute
Organization:
Jules Bordet Institute
Study Overview
Official Title:
FRAGRANCE TrialFemara Reanalysed Through Genomics for Response Assessment Calibration and Empowerment
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Find a genetic signature of de novo resistance to letrozole in adjuvant breast cancer
Detailed Description:
The aromatase inhibitors are drugs already approved for the treatment of breast cancer in the adjuvant and metastatic setting and have demonstrated a superiority when compared to other hormone therapy agents as tamoxifen FRAGRANCE is a trial of neoadjuvant hormone therapy activated in September 2004 at the Jules Bordet Institute The main objective of this study is to find a genetic signature of de novo resistance to letrozole The standard dose of letrozol 25 mgday is given orally during 4 months previous to the definitive breast surgery The advantages of the neoadjuvant setting are a the possibility to directly evaluate the response to therapy which is of great value to decide adjuvant treatment b the increase chance of performing breast conserving surgery c and because a tumor sample is obtained before and after treatment the identification of predictive markers of response or resistance to treatment including a genetic signature obtained using the microarray technology Eligible patients are women with early hormonal receptor positive breast cancer with any contra-indication or refusal to the administration of chemotherapy The side effects of letrozole are already well known and include more commonly hot flashes nausea and vomiting headache arthralgiamyalgia fatigue and oedema After surgery adjuvant treatment will be done according to the standard practice of the Institute considering the possibility of continuing letrozole for a total of at least 5 years if a satisfactory response is achieved The first part of this trial will include 49 patients
This trial will soon become a multicenter multinational trial of 160 patients
This trial will soon become a multicenter multinational trial of 160 patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None